Insulin-like growth factors and cancer: no role in screening. Evidence from the BUPA study and meta-analysis of prospective epidemiological studies

[1]  N. Wald,et al.  The efficacy of combining several risk factors as a screening test , 2005, Journal of medical screening.

[2]  P. Galan,et al.  A Prospective Study of the Insulin-Like Growth Factor Axis in Relation with Prostate Cancer in the SU.VI.MAX Trial , 2005, Cancer Epidemiology Biomarkers & Prevention.

[3]  Noel S Weiss,et al.  Prostate carcinoma incidence in relation to prediagnostic circulating levels of insulin‐like growth factor I, insulin‐like growth factor binding protein 3, and insulin , 2005, Cancer.

[4]  W. Willett,et al.  Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era , 2005, Cancer Causes & Control.

[5]  P. Stattin,et al.  High levels of circulating insulin-like growth factor-I increase prostate cancer risk: a prospective study in a population-based nonscreened cohort. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Matthias Egger,et al.  Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis , 2004, The Lancet.

[7]  F. Berrino,et al.  Prediagnostic levels of C‐peptide, IGF‐I, IGFBP ‐1, ‐2 and ‐3 and risk of endometrial cancer , 2004, International journal of cancer.

[8]  G. Stemmermann,et al.  Serum insulin-like growth factor I and subsequent risk of colorectal cancer among Japanese-American men. , 2003, American journal of epidemiology.

[9]  D. Albanes,et al.  Serum insulin-like growth factor I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men. , 2003, Cancer research.

[10]  M. Ando,et al.  Serum Insulin‐like Growth Factors, Insulin‐like Growth Factor‐binding Protein‐3, and Risk of Lung Cancer Death: A Case‐control Study Nested in the Japan Collaborative Cohort (JACC) Study , 2002, Japanese journal of cancer research : Gann.

[11]  M. Spitz,et al.  Serum insulin-like growth factor (IGF) and IGF-binding protein levels and risk of lung cancer: a case-control study nested in the beta-Carotene and Retinol Efficacy Trial Cohort. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[12]  F. Berrino,et al.  Circulating levels of insulin‐like growth factor‐I and risk of ovarian cancer , 2002, International journal of cancer.

[13]  E. Riboli,et al.  Insulin-like growth factor II and colorectal cancer risk in women. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[14]  S. London,et al.  Insulin-like growth factor I, IGF-binding protein 3, and lung cancer risk in a prospective study of men in China. , 2002, Journal of the National Cancer Institute.

[15]  E. Riboli,et al.  Plasma insulin-like growth factor 1, insulin-like growth factor binding protein 3, and risk of colorectal cancer: a prospective study in northern Sweden , 2002, Gut.

[16]  N. Probst-Hensch,et al.  IGF-1, IGF-2 and IGFBP-3 in prediagnostic serum: association with colorectal cancer in a cohort of Chinese men in Shanghai , 2001, British Journal of Cancer.

[17]  K. Helzlsouer,et al.  Null association between insulin-like growth factors, insulin-like growth factor-binding proteins, and prostate cancer in a prospective study. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[18]  R. Kaaks,et al.  Correspondence re: Giovannucci et al., A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women. Cancer Epidemiol. Biomark. Prev., 9: 345-349, 2000. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[19]  E. Riboli,et al.  A prospective study of insulin‐like growth factor‐I, IGF‐binding proteins‐1, ‐2 and ‐3 and lung cancer risk in women , 2001, International journal of cancer.

[20]  E. Metter,et al.  Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer. , 2000, The Journal of clinical endocrinology and metabolism.

[21]  E. Riboli,et al.  Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. , 2000, Journal of the National Cancer Institute.

[22]  W. Willett,et al.  A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[23]  N. Wald,et al.  When can a risk factor be used as a worthwhile screening test? , 1999, BMJ.

[24]  A. Renehan,et al.  Response: More About: Prospective Study of Colorectal Cancer Risk in Men and Plasma Levels of Insulin-Like Growth Factor (IGF)-I and IGF- Binding Protein-3 , 1999 .

[25]  Stampfer,et al.  Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. , 1999, Journal of the National Cancer Institute.

[26]  M. Stampfer,et al.  Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. , 1998, Science.